Vice Chairman of the Senate Select Committee on Intelligence Marco Rubio (R-FL) delivered opening remarks and questioned witnesses at a hearing on countering China’s influence in the United States. Watch Rubio’s opening remarks here as well as Part I and Part II of...
News
Latest News
Rubio-led Resolution to Raise Awareness for Spinal Cord Injuries Passes Senate
Approximately 302,000 Americans live with spinal cord injuries. To help these people achieve a better quality of life, there is a need to increase education and invest in research. U.S. Senators Marco Rubio (R-FL) and Tammy Baldwin (D-WI) successfully led a bipartisan...
Rubio, Warnock Reintroduce Protecting Sensitive Personal Data Act
Foreign investment is one of the legal means that adversaries, like China, can use to collect Americans’ data, exasperating both privacy and national security risks. To counter this, U.S. Senators Marco Rubio (R-FL) and Raphael Warnock (D-GA) reintroduced the...
ICYMI: Rubio Joins Special Report
U.S. Senator Marco Rubio (R-FL) joined Special Report with Bret Baier to discuss the impending government shutdown, the possibility of a Saudi-Israeli normalization deal, and the indictment of Senator Bob Menendez (D-NJ). See below for highlights and watch the full...
Rubio on DHS’ Continued Minimal Steps to Implement UFLPA
The U.S. Department of Homeland Security (DHS) announced three additions to the Uyghur Forced Labor Prevention Act (UFLPA) Entity List. These are the first additions by the Biden Administration since June. U.S. Senator Marco Rubio (R-FL), author of the bipartisan...
ICYMI: Rubio: Congress Should Think Before It Regulates AI
Congress should think before it regulates AI U.S. Senator Marco Rubio (R-FL) September 26, 2023 Washington Times To prevent next-generation computer programs from wreaking havoc on American society, [some members of Congress want] to enact comprehensive regulation at...
Rubio, Coons Introduce Legislation to Improve Domestic Biopharmaceutical Manufacturing Capabilities for Emerging Public Health Threats
Washington, D.C. — U.S. Senators Marco Rubio (R-FL) and Chris Coons (D-DE) introduced the Agility in Manufacturing Preparedness Act (S.3553) to require the U.S. Department of Health and Human Services (HHS) and the Biomedical Advanced Research and Development Authority (BARDA) to contract with the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) for the purpose of evaluating the current capacity and vulnerabilities of biopharmaceutical manufacturing in the United States. NIIMBL is a public-private partnership focused on improving manufacturing capabilities through its cutting-edge expertise, which would help the federal government enhance its preparedness and response capabilities for emerging public health threats. Rubio and Coons first introduced this bill as an amendment (#1917) to the Senate’s Endless Frontier Act in May 2021.
“America needs to be able to make things again, especially medicine,” Rubio said. “My new bill will help bring that back.”
“The current global health crisis has once again underscored the importance of sustained attention to potential threats and our preparedness for them. Expanding our manufacturing capacity in the United States and ensuring that it can respond to a variety of threats is imperative,” Coons said. “The Agility in Manufacturing Preparedness Act will put us in a position to improve our medical preparedness and support America’s health.”
The legislation specifically requires NIIMBL, in partnership with HHS, to:
- Review current domestic biopharmaceutical manufacturing capacity at HHS and its adaptability to various threats;
- Draft recommendations for developing, demonstrating, deploying, and advancing new domestic biopharmaceutical manufacturing technologies that address gaps in HHS’ current capabilities;
- Aligns federal technologies with private-sector capabilities, including those through BARDA’s new BioMAP initiative; and
- Identifies other opportunities and priorities to improve U.S. public health, medical preparedness and response capabilities, and domestic biopharmaceutical manufacturing capabilities.